Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endothelin receptor type A (ETA/EDNRA) is a G protein-coupled receptor that primarily binds endothelin-1, a potent vasoconstrictor peptide. Activation leads to vasoconstriction, sodium retention, and increased blood pressure. Overactivation contributes to hypertension, heart failure, renal failure, atherosclerosis, and cancer. ETA antagonists are under investigation for pulmonary arterial hypertension, chronic kidney disease, heart failure, and certain cancers.
ETA antagonists block the binding of endothelin-1 to the ETA receptor, preventing vasoconstriction, cell proliferation, and other downstream effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Endothelin Receptor Type A (ETA).